Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection (Q47182882)

From Wikidata

Jump to navigation Jump to search

scientific article published on 5 April 2009

Language	Label	Description	Also known as
English	Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection	scientific article published on 5 April 2009

Statements

scholarly article

1 reference

Europe PubMed Central

11 January 2018

http://europepmc.org/abstract/MED/19464545

Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection (English)

1 reference

Europe PubMed Central

11 January 2018

http://europepmc.org/abstract/MED/19464545

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

influenza vaccine

1 reference

based on heuristic

inferred from title

Valerie A. Ferro

6

1 reference

Europe PubMed Central

11 January 2018

http://europepmc.org/abstract/MED/19464545

1

object named as

Jamie F S Mann

1 reference

Europe PubMed Central

11 January 2018

http://europepmc.org/abstract/MED/19464545

author name string

Eisin Shakir

2

1 reference

Europe PubMed Central

11 January 2018

http://europepmc.org/abstract/MED/19464545

Katharine C Carter

3

1 reference

Europe PubMed Central

11 January 2018

http://europepmc.org/abstract/MED/19464545

Alexander B Mullen

4

1 reference

Europe PubMed Central

11 January 2018

http://europepmc.org/abstract/MED/19464545

James Alexander

5

1 reference

Europe PubMed Central

11 January 2018

http://europepmc.org/abstract/MED/19464545

language of work or name

0 references

publication date

5 April 2009

1 reference

Europe PubMed Central

11 January 2018

http://europepmc.org/abstract/MED/19464545

1 reference

Europe PubMed Central

11 January 2018

http://europepmc.org/abstract/MED/19464545

27

1 reference

Europe PubMed Central

11 January 2018

http://europepmc.org/abstract/MED/19464545

3643-3649

1 reference

Europe PubMed Central

11 January 2018

http://europepmc.org/abstract/MED/19464545

27

1 reference

Europe PubMed Central

11 January 2018

http://europepmc.org/abstract/MED/19464545

Role of secretory antibodies in the defence against infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.040

7 January 2021

Needle-free vaccine delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.040

7 January 2021

Oral vaccine models: multiple delivery systems employing tetanus toxoid.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.040

7 January 2021

Mucosal vaccines: the promise and the challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.040

7 January 2021

Mucosal immunity and vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.040

7 January 2021

Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.040

7 January 2021

Protection of mice against an influenza virus infection by oral vaccination with viral nucleoprotein incorporated into immunostimulating complexes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.040

7 January 2021

Novel adjuvant based on a proteoliposome-derived cochleate structure containing native lipopolysaccharide as a pathogen-associated molecular pattern

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.040

7 January 2021

Optimisation of a lipid based oral delivery system containing A/Panama influenza haemagglutinin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.040

7 January 2021

Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.040

7 January 2021

Cholera toxin B subunit conjugated bile salt stabilized vesicles (bilosomes) for oral immunization.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.040

7 January 2021

Oral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.040

7 January 2021

Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.040

7 January 2021

Vesicle size influences the trafficking, processing, and presentation of antigens in lipid vesicles.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.040

7 January 2021

Accurate determination of adjuvant-associated protein or peptide by ninhydrin assay

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.040

7 January 2021

Innovative strategies for the oral delivery of drugs and peptides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.040

7 January 2021

Antigen delivery to mucosa-associated lymphoid tissues using liposomes as a carrier

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.040

7 January 2021

War and peace at mucosal surfaces

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.040

7 January 2021

Freshly isolated Peyer's patch, but not spleen, dendritic cells produce interleukin 10 and induce the differentiation of T helper type 2 cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.040

7 January 2021

Selective development of T helper (Th)2 cells induced by continuous administration of low dose soluble proteins to normal and beta(2)-microglobulin-deficient BALB/c mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.040

7 January 2021

Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.040

7 January 2021

Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.040

7 January 2021

Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.040

7 January 2021

Translation of an experimental oral vaccine formulation into a commercial product.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.040

7 January 2021

The IgA and subclass IgG responses and protection in mice immunised with influenza antigens administered as ISCOMS, with FCA, ALH or as infectious virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.040

7 January 2021

Identifiers

10.1016/J.VACCINE.2009.03.040

1 reference

Europe PubMed Central

11 January 2018

http://europepmc.org/abstract/MED/19464545

release_atmguqjshza6hgwyfhrgm37rfi

1 reference

https://api.fatcat.wiki/v0/release/atmguqjshza6hgwyfhrgm37rfi

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

11 January 2018

http://europepmc.org/abstract/MED/19464545

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47182882&oldid=2143860238"